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ABSTRACT The intracellular protozoan Toxoplasma gondii dramatically reprograms the transcriptome of host cells it infects,
including substantially up-regulating the host oncogene c-myc. By applying a flow cytometry-based selection to infected mouse
cells expressing green fluorescent protein fused to c-Myc (c-Myc–GFP), we isolated mutant tachyzoites defective in this host
c-Myc up-regulation. Whole-genome sequencing of three suchmutants led to the identification ofMYR1 (Myc regulation 1;
TGGT1_254470) as essential for c-Myc induction. MYR1 is a secreted protein that requires TgASP5 to be cleaved into two stable
portions, both of which are ultimately found within the parasitophorous vacuole and at the parasitophorous vacuole membrane.
Deletion ofMYR1 revealed that in addition to its requirement for c-Myc up-regulation, the MYR1 protein is needed for the abil-
ity of Toxoplasma tachyzoites to modulate several other important host pathways, including those mediated by the dense gran-
ule effectors GRA16 and GRA24. This result, combined with its location at the parasitophorous vacuole membrane, suggested
that MYR1might be a component of the machinery that translocates Toxoplasma effectors from the parasitophorous vacuole
into the host cytosol. Support for this possibility was obtained by showing that transit of GRA24 to the host nucleus is indeed
MYR1-dependent. As predicted by this pleiotropic phenotype, parasites deficient inMYR1were found to be severely attenuated
in a mouse model of infection. We conclude, therefore, that MYR1 is a novel protein that plays a critical role in how Toxoplasma
delivers effector proteins to the infected host cell and that this is crucial to virulence.
IMPORTANCE Toxoplasma gondii is an important human pathogen and a model for the study of intracellular parasitism. Infec-
tion of the host cell with Toxoplasma tachyzoites involves the introduction of protein effectors, including many that are initially
secreted into the parasitophorous vacuole but must ultimately translocate to the host cell cytosol to function. The work reported
here identified a novel protein that is required for this translocation. These results give new insight into a very unusual cell biol-
ogy process as well as providing a potential handle on a pathway that is necessary for virulence and, therefore, a new potential
target for chemotherapy.
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Toxoplasma gondii is an obligate intracellular parasite of greatmedical importance, as infections in immunosuppressed pa-
tients often lead to life-threatening encephalitis. While Toxo-
plasma bradyzoites localize to specific tissues (brain, skeletal mus-
cles, and heart) (1) during the chronic phase, the acute stages of
infection involve tachyzoites that are able to infect virtually any
nucleated cell. Toxoplasma’s intracellular lifestyle is dependent on
the ability of the parasite to regulate host cell processes via its
secreted effectors. For example, the rhoptry protein ROP16 regu-
lates the immunologically important host transcription factors
STAT1 (2), STAT3 (3), STAT5 (4), and STAT6 (5), causing pro-
found transcriptional changes shortly after invasion. Further ex-
amples of Toxoplasma’s ability to specifically regulate host func-
tions are its dense granule effectors GRA15 (6), GRA16 (7), and
GRA24 (8), which regulate the NF-B, p53, and p38 MAP kinase
(MAPK) host pathways, respectively.
We have recently discovered that Toxoplasma tachyzoites also
specifically and actively induce host c-Myc upon infection (9).
c-Myc is a key transcription factor that regulates critical host cell
processes such as cell cycle progression, cell metabolism, and ap-
optosis (10, 11), and several of these c-Myc-regulated processes
appear to be modulated in Toxoplasma-infected cells (12). In ad-
dition, and likely as a direct consequence of its up-regulation,
many of the known gene targets of c-Myc have also been reported
to be transcriptionally up-regulated during Toxoplasma infection
(9). The up-regulation of c-Myc is likely mediated by one ormore
novel effectors, since none of the previously identifiedToxoplasma
effectors appear to play a role (7, 9).
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The mechanism by which secreted effectors reach the host cy-
tosol in Toxoplasma-infected cells is not known. In the related
malaria parasites Plasmodium spp., proteins are translocated
across the parasitophorous vacuole membrane (PVM) via the
PTEX complex (13–15). Toxoplasma has recognizable ortho-
logues of some components of this complex, but recent reports
show that these operate in different ways; e.g., the Toxoplasma
orthologue of EXP2 is GRA17, but recent work showed that this
protein serves as a transporter of small molecules (3,000 Da),
not proteins (16).
To further explore the process by which Toxoplasma effectors
operate, we chose a genetic approach that exploits the fact that
Toxoplasma tachyzoites up-regulate c-Myc and the existence of
faithful c-Myc reporter systems. Here we describe the use of such
a screen to identify mutants deficient in a novel Toxoplasma pro-
tein that is secreted into the parasitophorous vacuole (PV) and is
necessary for host c-Myc induction. We show that mutations in
this gene, which we have dubbed MYR1 (Myc regulation 1), are
pleiotropic with a pronounced defect in the ability of tachyzoites
to manipulate several host pathways, and we propose a role for
MYR1 in protein translocation across the PVM.
RESULTS
Isolation ofToxoplasmamutants that fail to induce c-Myc. For-
ward genetic screens have previously identified important Toxo-
plasma proteins involved in various functions (17–20). Such an
approach is facilitated by the fact that the Toxoplasma genome is
haploid, and thus, single mutations often give rise to discrete phe-
notypes. To further investigate howToxoplasma tachyzoites inter-
act with the host cell, therefore, we designed a high-throughput
genetic screen to isolate mutants defective in their ability to mod-
ulate a known and easily studied pathway, the up-regulation of
c-Myc. The major requirement for such a screen is a reporter cell
that allows easy detection of c-Myc expression levels. For this, we
first attempted several plasmid-based systems involving the c-Myc
promoter driving reporters such as GFP in established cell lines;
unfortunately, however, none showed up-regulation upon infec-
tion with Toxoplasma tachyzoites (data not shown). This sug-
gested that the up-regulation required c-myc to be in its natural
chromosomal location, where it is known to be regulated by a
complex array of enhancers, including at least one that is 400
kbp distant (21).
To overcome the limitation of plasmid-based reporters, we
examined bone marrow macrophages (BMMs) from mice engi-
neered to express green fluorescent protein (GFP) fused to the N
terminus of c-Myc and expressed from the native c-myc locus
(22). BMMs were isolated from the mice and infected at a multi-
plicity of infection (MOI) of 0.25 with either Toxoplasma RH
mCherry orNeospora caninumNC-1 mCherry (9) or were mock-
infected. Approximately 24 h postinfection (hpi), flow cytometry
was used to distinguish between infected (mCherry-positive) and
uninfected (mCherry-negative) cells and to analyze GFP levels in
FIG 1 Genetic screen to isolate Toxoplasmamutants that fail to induce c-Myc. (A) Flow cytometry histogram of BMMs expressing c-Myc–GFP infected with
Toxoplasma wild-type tachyzoites (RH) or Neospora tachyzoites or mock-infected. The gate was set on highly infected cells. The y axis shows relative cell count
for each population (normalized to mode), and the x axis shows green fluorescence intensity. (B) Selection of mutants that fail to induce c-Myc. BMM
c-Myc–GFP reporter cells were infected with a mutagenized population of RH tachyzoites and sorted for low GFP fluorescence. This was repeated until a
homogeneous population was obtained that induced low GFP fluorescence. The GFP fluorescence profiles for the mutagenized population after 3, 5, and 7
rounds of selection are shown. (Histograms for first two sorts were similar to the one for sort 3 and were omitted.) The profiles for cells infected with wild-type
RH and Neospora tachyzoites are shown for comparison. The x and y axes are as described for panel A.
Franco et al.
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both populations (Fig. 1A). The results showed that, compared to
mock-infected reporter cells, Toxoplasma-infected cells exhibited
a marked increase in green fluorescence. Infection with Neospora
showed no c-Myc up-regulation, as previously reported (9).
Having identified a reporter system that recapitulates the
Toxoplasma-induced up-regulation of c-Myc, we next designed a
genetic screen for Toxoplasma mutants that are deficient in this
process. Mutagenized Toxoplasma RH parasites expressing
mCherrywere used to infect the c-Myc–GFP reporter BMMs at an
MOI of 0.25. A low multiplicity of infection was used to ensure
that most reporter cells were infected with only one parasite,
which was confirmed visually by fluorescence microscopy. Toxo-
plasmawild-type-infected cells andmock-infected cells were used
as positive and negative controls for c-Myc induction, respec-
tively. Cells with high levels of red fluorescence but little or noGFP
signal were then selected by fluorescence-activated cell sorting
(FACS). Neospora-infected cells were used to establish selection
gates for the enrichment of mutants. Parasites in the selected cells,
representing between 1 and 5% of the total infected population,
were expanded by growth in human foreskin fibroblasts (HFFs),
and selection in c-Myc-reporter BMMs was repeated a further
seven times. A phenotypically distinct population began to
emerge after 5 enrichments, and after a further 2 rounds of selec-
tion, the mutant phenotype (failure to induce c-Myc–GFP) was
uniformly present in the entire population (Fig. 1B). This popu-
lationwas dubbedMFM1 (Magdalena Franco c-Mycmutant pop-
ulation 1), and parasite clones derived from this population were
sequentially numbered MFM1.1, MFM1.2, etc.
To obtain independent mutants for the purposes of whole-
genome sequencing analysis, the screen was repeated with an in-
dependently mutagenized population of Toxoplasma parasites.
This time, more stringent gates were used during selection of the
mutant parasites (selecting for the lowest 1% of infected cells in
terms of green fluorescence), and only 5 rounds of selection were
necessary to isolate parasites deficient in c-Myc induction (data
not shown). This population was dubbed MFM2 and was sub-
jected to limiting dilution to yield the putative clones, MFM2.1,
MFM2.2, etc.
To verify that the isolated Toxoplasma mutant strains are in-
deed deficient in c-Myc up-regulation, c-Myc levels in lysates pre-
pared from HFFs infected with each of three mutant lines,
MFM1.1, MFM2.1, and MFM2.2, representing the two indepen-
dently generated mutant pools, were analyzed by Western blot-
ting.Mock-infected andNeospora-infected cells served as negative
controls for c-Myc induction, and cells infected with wild-type
Toxoplasma were used as a positive control. The results (Fig. 2A)
showed that cells infected with two of the three cloned mutants,
MFM1.1 and MFM2.2, showed no detectable c-Myc, indicating
the selection strategy was successful in yielding Toxoplasma mu-
tants deficient in c-Myc up-regulation. MFM2.1 had an interme-
diate phenotype, which is discussed further below.
Whole-genome sequence analysis reveals a candidate gene,
TGGT1_254470. To identify the Toxoplasma gene(s) involved in
c-Myc up-regulation, the MFM1.1, MFM2.1, and MFM2.2 mu-
tantswere analyzed bywhole-genome sequencing. Sequence com-
parison relative to the parental reference revealed 5, 7, and 6 single
nucleotide variations (SNVs), respectively, in chromosomal cod-
ing regions of MFM1.1, MFM2.1, and MFM2.2 (Table 1). These
results showed that although they came from the same screen,
MFM2.1 and MFM2.2 are independent mutants, as each con-
tained a different set of SNVs. The independence of MFM1.1,
whichwas isolated from the first screen, was also confirmed by the
sequencing. MFM2.1 had no SNVs with a read frequency over
80% but several within the ~40-to-60% range (Table 1). This in-
dicates that the sample containing MFM2.1 is in fact a mix of two
FIG 2 Characterization of Toxoplasma mutants that fail to up-regulate c-Myc in host cells. (A) Human foreskin fibroblasts (HFFs) were infected with
wild-type parasites (RH) or mutant strains MFM1.1, MFM2.1, and MFM2.2. Neospora- and mock-infected fibroblasts were used as negative controls for
c-Myc induction. Lysates from infected cells were prepared at 20 hpi, and host c-Myc levels were analyzed by Western blotting using anti-human c-Myc
antibodies. Anti-hGAPDH staining was used as a loading control for host (human) protein, and anti-SAG1 staining was used to show comparable levels
of Toxoplasma infection. Each row is derived from the same exposure of the same blot; the white vertical separator shows where irrelevant data were
removed from the image. (B) Schematic diagram of wild-type and mutant TGGT1_254470 (MYR1) protein. Numbers indicate amino acid positions
relative to the predicted N terminus of the unprocessed protein. The signal peptide (SP) is as predicted by the SignalP 4.1 tool (http://www.cbs.dtu.dk/
services/SignalP/) and ToxoDB (http://www.toxodb.org) and phosphorylated serine (S*) residues were determined by phosphoproteomic analysis (24).
The region expressed as a recombinant version of MYR1 representing amino acids 155 to 328 to generate an N-terminus-specific antibody is indicated by
the solid line [rMYR1(155–328)]. Transmembrane domains are as predicted by the TMHMM algorithm and ToxoDB (http://www.cbs.dtu.dk/services/
TMHMM-2.0/), and the position of the first residue of each is indicated. A likely ASP5 cleavage site (RRLSE) is as described in the text. Mutant versions
of MYR1, as predicted by sequencing strainsMFM1.1, MFM2.1, andMFM2.2, are also shown. The letters and numbers to the right of each schematic show
the original coding function and position of the nonsense mutation in each.
MYR1, a Novel Protein in Toxoplasma Virulence
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lines, consistent with its intermediate phenotype in terms of
c-Myc up-regulation, as shown in Fig. 2A.
In addition to the SNVs in chromosomal genes shown in Ta-
ble 1, mutations might also be present in genes present on rela-
tively short contigs that have yet to be confidently positioned on
any chromosome, likely because they are tandemly duplicated
genes that are difficult to unambiguously assemble. Identifying
mutations in the latter set is particularly challenging because the
short sequence reads often cannot be unambiguously assigned to
one or other of the tandemly repeated genes and a false assignment
may erroneously be taken as an SNV. We did not attempt to re-
solve SNVs in such contigs and it is possible, therefore, that addi-
tional coding SNVs, beyond those shown in Table 1, exist within
the mutants.
Of all the identified SNVs, only one Toxoplasma gene (des-
ignated TGGT1_254470 in ToxoDB v.10.0; http://www.toxod-
b.org) carried an alteration in two ormoremutants; in fact, it was
altered in all three mutants (Table 1), each of which carried a
nonsense mutation at a different position (Fig. 2B). Moreover,
TGGT1_254470was the only gene to harbor a nonsense mutation
in any of the three mutants (Table 1). These data strongly sug-
gested that TGGT1_254470 is necessary for c-Myc induction in
Toxoplasma-infected host cells, and it was therefore dubbed
MYR1 for its essential role in c-Myc regulation.
MYR1 is located on chromosome III and is predicted by Tox-
oDB (v25) to have 4 or 5 introns, depending on the strain. Aggre-
gate RNA-Seq data in ToxoDB, however, clearly show that inmost
strains, the extra intron predicted in TgME49_254470 (positions
1758697 to 1759101) is rarely, if ever, spliced out, and this region
is instead fully represented in the bulk of the final mRNA gener-
ated. This impacts the predicted open reading frame and extends
it 234 bp in the 5= direction, relative to what is shown for
TgME49_254470, resulting in a different predicted start codon
(position 1758990, as we have now noted in the comment section
for this gene in ToxoDB). Use of this upstream start codon results
in the presence of a strongly predicted signal peptide by SignalP
4.1 with a discrimination score (D score) of 0.77, where any score
above 0.45 is judged significant. This is consistent with the fact
that the MYR1 protein is secreted from the parasite (see below).
We conclude, therefore, that the extra intron predicted forMYR1
is typically not spliced out and that the true start site for transla-
tion is at nucleotide 1758990.
Expressed sequence tag data, microarray data, and RNA-Seq
data, also available on ToxoDB (v25), show that this gene is abun-
dantly expressed across the three major infectious stages of Toxo-
plasma, tachyzoites, bradyzoites, and sporozoites but is expressed
little if at all (5% of the RPKM [reads per kilobase per million]
values for tachyzoites) in the intraepithelial stages in the cat gut
(23–27). Its function, therefore, may not be key to the sexual cycle
of the parasite that occurs exclusively in felines.
Multiple sequence alignment of nucleotide and protein se-
quences using the Clustal Omega alignment tool on EMBL-EBI
website (http://www.ebi.ac.uk) revealed that this protein is highly
conserved (99% identity) among the three canonical strains, RH
(type I), ME49 (type II), and VEG (type III). Likewise, it is ex-
pressed at similar levels in tachyzoites from these three strains
(ToxoDB [v25]). These similarities were as expected given that all
three major types exhibit the c-Myc induction phenotype (9).
MYR1 encodes a novel protein with two predicted transmem-
brane domains located near its C terminus (Fig. 2B). PsiBLAST
analysis of the entire protein sequence revealed no predicted func-
tion and no homology to proteins outside its closest relatives,
TABLE 1 Coding mutations in mutant strains as detected by whole-genome sequencinga
Clone and
chromosome
SNV
position
%
confidence
Codon
(WT/mut)b
Amino acid
changec Gene
Predicted
function
MFM1.1
TGGT1_chrX 6416305 97 tgC/tgG C1296W TGGT1_214830 Hypothetical protein
TGGT1_chrVIII 1852637 100 caT/caA H643Q TGGT1_232100 RAP domain-containing protein
TGGT1_chrVIII 216920 100 gAa/gGa E135G TGGT1_229380 Hypothetical protein
TGGT1_chrXII 3209479 100 gTc/gGc V125G TGGT1_247350 Thioredoxin domain-containing protein
TGGT1_chrIII 1740887 100 taT/taA Y281* TGGT1_254470 Hypothetical protein
MFM2.1
TGGT1_chrVIIb 3288737 42 tCa/tTa S151L TGGT1_258580 Rhoptry protein ROP17
TGGT1_chrIX 2870406 42 Aaa/Gaa K526E TGGT1_289190 Tetratricopeptide repeat-containing protein
TGGT1_chrXI 3283667 43 gGa/gAa G635E TGGT1_313370 Hypothetical protein
TGGT1_chrVI 583819 46 gaG/gaT E294D TGGT1_239365 Formyl transferase domain-containing protein
TGGT1_chrX 4899763 46 Acc/Ccc T781P TGGT1_235640 Formyl transferase domain-containing protein
TGGT1_chrVIIa 3223402 56 aTt/aCt I53T TGGT1_202445 Hypothetical protein
TGGT1_chrIII 1741174 41 tTa/tGa L377* TGGT1_254470 Hypothetical protein
MFM 2.2
TGGT1_chrV 989081 100 Ggc/Agc G51S TGGT1_213520 Peptidase M20D, amidohydrolase
TGGT1_chrVIII 4035211 100 Tat/Cat Y170H TGGT1_272370 Hypothetical protein
TGGT1_chrX 6416305 100 tgC/tgG C1296W TGGT1_214830 Hypothetical protein
TGGT1_chrXII 6308563 100 Aag/Gag K2346E TGGT1_277940 Hypothetical protein
TGGT1_chrXII 1807927 100 Tca/Aca S601T TGGT1_217480 Hypothetical protein
TGGT1_chrIII 1740978 100 Cga/Tga R312* TGGT1_254470 Hypothetical protein
a The position and nature of all coding SNVs in chromosomal genes in each mutant are listed. Only mutations that were supported by at least 80% of the reads in MFM1.1 and
MFM2.2 or 40% of the reads in MFM2.1 were considered SNVs.
b WT, wild type; mut, mutant. Capital letters indicate the mutated nucleotides.
c *, Stop codon.
Franco et al.
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Hammondia hammondi and Neospora caninum. The orthologue
of MYR1 present in the very closely related H. hammondi
(HHA_254470) is 87% identical at the amino acid level, as ex-
pected, but in N. caninum (NCLIV_008760), there is only ~45%
predicted protein identity relative to the Toxoplasma (GT1) pro-
tein (ToxoDB v25). No convincing homologue is detectable in
Sarcocystis neurona or the more distantly related apicomplexan
genera Eimeria and Plasmodium. These results suggest a function
specific to a subset of the tissue-dwelling coccidia.
MYR1 is necessary for host c-Myc induction.To confirm that
MYR1 is involved in the c-Myc induction phenotype, we gener-
ated a targeted deletion of the MYR1 locus in RH type I Toxo-
plasma and produced a complemented version of this myr1
strain in which a C-terminally hemagglutinin (HA)-tagged ver-
sion of the MYR1 gene is ectopically expressed in the knockout
(RHmyr1::MYR1; see Materials and Methods). Successful dele-
tion of the MYR1 locus in the myr1 line was confirmed by PCR
(data not shown); Western blots using mouse antiserum raised
to a recombinant MYR1 (representing amino acids 155 to 328
of the protein) (Fig. 2B; also, see Materials and Methods) fur-
ther confirmed both the deletion and successful complementa-
tion (Fig. 3A).
HFFs were infected with the deleted and complemented para-
sites, and lysates of infected cells were prepared at 20 hpi. Wild-
type and mock-infected cells served as positive and negative con-
trols for c-Myc induction, respectively. The results (Fig. 3A)
showed a much-reduced level of host c-Myc in cells infected with
the myr1 parasites compared to cells infected with wild-type or
complemented parasites, indicating that MYR1 is indeed neces-
sary for c-Myc induction.
MYR1 is cleaved in a process dependent on Toxoplasma’s
ASP5 protease. Although the MYR1 protein is predicted to be
about 80 kDa after removal of the signal peptide, Western blots of
purified wild-type RH (RH-WT) and RHmyr1::MYR1 comple-
mented parasites revealed two bands using the anti-MYR1 anti-
body that migrate as if they were ~105 kDa and ~80 k Da, respec-
tively (Fig. 3B). Western blots of the C-terminally HA-tagged
RHmyr1::MYR1 line using anti-HA antibodies also yielded a
band migrating at ~105 kDa, but instead of the ~80-kDa band,
there was a band that migrated at ~32 kDa (Fig. 3C). Given that
the recombinant protein used to generate the anti-MYR1 antibod-
ies corresponded to the N-terminal portion (Fig. 2B), and the
~32-kDa band was detected only using the anti-HA antibodies
and not with the anti-MYR1 antibodies, these results indicate that
MYR1 is initially synthesized as a precursor that migrates as if it is
~105 kDa and that this protein is then proteolytically cleaved to
yield fragments corresponding to about the N-terminal three-
fourths and C-terminal one-fourth of the protein. The slow mi-
gration of the full-lengthMYR1 and the N-terminal three-fourths
could be a result of posttranslational modifications and/or
MYR1’s acidic pI (~5.0).
Near the predicted cleavage site based on size is the amino acid
sequence RRLSE (Fig. 2B). This is reminiscent of the Plasmodium
export element, or PEXEL motif (28, 29), that is processed by
plasmepsin V, an aspartyl protease in Plasmodium parasites (30–
32). As recently shown by Coffey et al., aspartyl protease 5 (ASP5),
a Toxoplasma orthologue of the Plasmodium plasmepsin, is nec-
essary forMYR1 cleavage andmutation of the RRLSE sequence to
ARLSE abrogates cleavage, strongly suggesting that MYR1 is
cleaved byASP5within this pentapeptide, likely between the L and
FIG 3 MYR1 is a secreted protein that is necessary for c-Myc induction. (A) HFFs were infected at anMOI of 1 with the indicated strain and lysed at 20 hpi, and
lysates were analyzed by Western blotting using anti-MYR1 antibodies and anti-HA antibodies to detect endogenous and recombinant MYR1 levels. Rabbit
anti-c-Myc antibodies were used to assess the levels of c-Myc in each sample. Anti-GAPDH and anti-SAG1 antibodies served as loading controls for cells and
parasites, respectively. (B) As described for panel A, except themonolayers were scrape-syringed and tachyzoites were purified away from host cell material prior
to the lysate being prepared. An additional band at ~105 kDa is apparent in these lysates. (C) Anti-MYR1 and anti-HA blots of cell lysate prepared from HFFs
infected with complemented (RHmyr1::MYR1) parasites. These blots were overexposed so the slow-running band (~105 kDa) corresponding to full-length
MYR1 and detected by both antibodies can be seen.
MYR1, a Novel Protein in Toxoplasma Virulence
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S, based on the specificity of ASP5 (33). The role of this cleavage is
not known, but it could be related to the trafficking and/or bio-
chemical function of MYR1.
MYR1 is secreted into the PV and associates with the PVM.
The complemented strain used in the studies described above used
an ectopically expressed version of MYR1, driven off the GRA1
promoter. GRA1 is a very abundantly expressed dense granule
protein, and this strain served the purpose of showing that com-
plementation of themyr1mutant with ectopicMYR1 rescues the
c-Myc regulation phenotype. For determining the true localiza-
tion of MYR1, however, we needed to be sure the protein was
expressed at normal levels and at the correct time in the parasite’s
cell cycle. We therefore also created a strain where the native
MYR1 locus was engineered to encode a C-terminal HA tag (RH:
MYR1-HA). Control experiments confirmed that the expression
of this tagged MYR1 were comparable to the levels seen in wild-
type parasites (Fig. 4A).
HFFs were infected with RH:MYR1-HA, fixed with methanol
at 12 hpi, and examined by confocal microscopy using antibodies
to the HA tag (to detect the C-terminal domain) or antibodies to
the N-terminal rMYR1(155–328). Rabbit antibodies to GRA7
were used as a counterstain and a marker for a secreted protein.
The results showed that, like GRA7, both the C- and N-terminal
domains ofMYR1 are abundantly present within the PVwith rare
puncta within the parasites themselves (Fig. 4B). Staining for both
domains was also seen at the PVM, especially in cells that had
vacuoles containing only one or two parasites. Colocalizationwith
anti-GRA7 signal was seen in all three areas although the data did
not allow us to reach a firm conclusion on whether MYR1 and
GRA7 originate in the same structures (dense granules) within the
parasite. This ambiguous, “dense-granule-like” staining is similar
to what has been reported for GRA24 (8). Overall, however, these
data clearly show that, like GRA7, MYR1 is a secreted protein and
that both domains are present in the PV space, with a considerable
amount at the PVM itself.
Consistent with these localization results, a recent phospho-
proteomics study of tachyzoite-infected fibroblasts byTreeck et al.
(24) indicated that MYR1 is specifically phosphorylated outside
the parasite (i.e., within the PV and/or the infected host cytosol)
(34). The positions of the four phosphorylated serines identified
in that study are depicted in Fig. 2B.
MYR1 is necessary for Toxoplasma’s impact on host cell cy-
cle. c-Myc is a potent transcription factor whose up-regulation
likely affects the host cell in profound ways. One such impact
might be on progression through the cell cycle, given c-Myc’s
demonstrated role in this key pathway (10, 11, 35–38). To exam-
ine this, we used propidium iodide to stain host cells that were first
infected with either wild-type RH tachyzoites or RHmyr1. The
results (Fig. 5) showed that relative to uninfected cells, RH infec-
tion results in a profound dysregulation of the host cell cycle, with
many cells showing four times the normal complement of DNA,
i.e., 8n. The ploidy profile of host cells infected with the myr1
mutants, on the other hand, was indistinguishable from that of
uninfected cells. This indicates thatMYR1 is needed for Toxoplas-
ma’s ability to disrupt the host cell cycle, possibly through its role
in the up-regulation of c-Myc. Alternatively, the role of MYR1 in
this effect on host cell cycle could be through an indirect effect
involving other parasite effectors or host proteins other than
c-Myc.
FIG 4 MYR1 N-terminal and C-terminal domains localize to the parasitophorous vacuole membrane and PV space. (A) C-terminal HA-tagging of the
endogenousMYR1 locus does not affect its expression levels. Extracellular tachyzoites of the RH and C-terminally tagged RH:MYR1-HA strains were lysed
in radioimmunoprecipitation assay (RIPA) buffer and analyzed by Western blotting using anti-MYR1(155–328) and anti-HA antibodies. GRA7 anti-
bodies were used to assess equal loading. (B) The N-terminal and C-terminal domains of MYR1 localize to the PV and PVM. HFFs were infected with the
RH:MYR1-HA strain and fixed with methanol at 12 hpi. The fixedmonolayers were stained with DAPI and antibodies to HA orMYR1 N-terminus (green)
and GRA7 (red).
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MYR1 is dispensable for a subset of host interactions medi-
ated by dense granule proteins. To better understand the func-
tion of MYR1 and to test the possibility that it is a part of the
machinery that delivers or otherwise potentiates effectors rather
than being an effector itself, we sought to determine whether the
myr1mutant was deficient in other host interactions, especially
those mediated by known dense granule effectors. The first such
process we tested was the phenomenon of host mitochondrial
association (HMA) which we have previously reported to be me-
diated by a secreted dense granule protein known as MAF1 (mi-
tochondrial association factor 1) (39). MAF1 is expressed by type
I strains at the PV membrane (PVM), where it binds to host mi-
tochondria. If MYR1 is involved in the trafficking or maturation
of all dense granule proteins, then the myr1 mutants should be
deficient in HMA. HFFs were therefore infected with wild-type
RH, RHmyr1, and RHmyr1::MYR. As a control for the identity
of the parasite lines, we first tested and confirmed that they had the
expected phenotypes for c-Myc induction (Fig. 6A). Parallel in-
fections were then fixed and assessed for mitochondrial recruit-
ment by staining with anti-TOM20. The results (Fig. 6B) showed
that the RHmaf1 parasites exhibited the expected lack of HMA,
whereas cells infected with the RHmyr1mutants showed strong
HMA, indistinguishable from that of cells infected with wild-
type parasites. These results were confirmed by electron mi-
croscopy (data not shown). Hence, MYR1 is not necessary for
efficient HMA.
The next phenotype we tested was the ability to induce NF-B
nuclear localization. This is a trait of type II strains, not the more
commonly studied type I strains such as RH, and is mediated by
GRA15, which localizes to the PV after invasion (6). To determine
whether MYR1 plays a role in GRA15’s ability to induce NF-B,
we engineered a type II strain (ME49) that lacks MYR1 and then
assessed this strain for its ability to cause up-regulation of NF-B.
The results (Fig. 6C) showed that the absence of MYR1 has no
effect on the ability to induceNF-B, further arguing thatMYR1 is
not part of the general machinery for dense granule protein syn-
thesis, secretion, and subsequent translocation to the PVM.
MYR1 is necessary for the action of two dense granule pro-
teins that cross the PVM and accumulate in the host nucleus.
Some interactions of Toxoplasma tachyzoites are mediated by ef-
fectors that are translocated across the PVM and then act within
the host nucleus, one example being GRA24, which mediates the
sustained activation of p38 MAP kinase (8). To test if MYR1 im-
pacts such an effector, we asked whether MYR1 is necessary for
tachyzoites to activate host p38 MAPK relative to infection. The
results (Fig. 7A and D) showed that the RHmyr1 mutant is in-
deed unable to cause substantial activation of p38, indicating a
role for MYR1 in this process. Although we cannot exclude the
possibility that MYR1 is an accessory effector that works in part-
nership with GRA24, the fact that ectopic expression of GRA24
alone in uninfected cells can induce the changes in p38 (8) argues
against the possibility of an accessory factor and suggests, instead,
that MYR1 is part of the machinery necessary for maturation
and/or translocation of GRA24 across the PVM.
GRA16 is another dense granule effector that traffics to the host
cell nucleus, in this case intersecting with p53 and PP2A phospha-
tase pathways (7). To determine ifMYR1 is necessary for the func-
tion of this effector, we assessed the ability of the RHmyr1 mu-
tant to induce PP2A-PR55B translocation from the cytosol to the
nucleus in infected cells. The results (Fig. 7B and E) showed that
the RHmyr1 mutant is indeed defective in this respect, while
the RHmyr1::MYR1 complemented strain exhibited a rescued
(wild-type) phenotype. These results are consistent with a gen-
eral role in the maturation and/or trafficking of dense granule
effectors that are transported across the PVM and reach the
host cytosol.
The final host interaction assessed was the ability of Toxo-
plasma tachyzoites to specifically block the up-regulation and nu-
clear translocation of IRF1 in response to IFN-. This ability is a
property of all three major strains (40), but the effector involved
has not been identified. To test if MYR1 affects this pathway, we
infected host cells with RH-WT or RHmyr1 strains and then
performed immunofluorescence assays using antibodies to IRF1.
The results (Fig. 7C and F) showed that the RHmyr1mutants are
completely defective in their ability to suppress the IRF1 response.
To prove that this was related to the absence of MYR1, the
RHmyr1::MYR1 complemented strain was examined and found
to rescue the defect. Hence, either MYR1 is the effector responsi-
ble for IRF1 up-regulation, or, like GRA16 and GRA24, the effec-
tor involved is dependent on MYR1 for its functionality.
MYR1 is necessary for trafficking of GRA24 to the host nu-
cleus. To directly test if MYR1 plays a role in the trafficking of
Toxoplasma’s exported effectors, we examined the location of
GRA24 in the RHmyr1mutants by immunofluorescence analy-
sis of infected cells. To do this, we introduced a plasmid expressing
an epitope-tagged GRA24 into the RH-WT, RHmyr1 and
RHmyr1::MYR1 strains and then stained the infected cells at
20 hpi. The results (Fig. 8) showed that the RHmyr1mutants are
indeed defective in their ability to traffic GRA24 to the host nu-
cleus, whereas RH-WT and the RHmyr1::MYR1 complemented
strains show efficient translocation. This indicates that MYR1
plays a crucial role in the physical translocation of GRA24 from
the PV into the host cell.
MYR1 mutants exhibit no growth defect in vitro but have
decreased virulence in mice. Given MYR1’s involvement in sev-
FIG 5 The cell cycle is dysregulated in cells infected by wild-type parasites but
not in cells infected withmyr1mutants. Propidium iodide assessment of cell
DNA content was performed in RAW264.7 cells at 19 hpi with RH and
RHmyr1 parasites expressing mCherry. Cells were fixed with methanol,
stained with propidium iodide, and then assessed on an LSRII flow cytometer.
The three peaks represent cells in G0/G1 (2n), cells in G2/M (4n), and aneup-
loid cells (~8n).
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eral key pathways involving interactions with the host, we assessed
its growth phenotype in vitro and virulence in vivo. The ability
of the myr1 parasites to grow in HFFs in vitro was first mea-
sured. The results (Fig. 9A and C) showed that growth of both
the RHmyr1 and ME49myr1 parasites in vitro was indistin-
guishable from that of wild-type RH and ME49, respectively,
consistent with the fact that the pathways shown here to be
dependent on MYR1 are generally dispensable for growth in
HFFs.
To determine if themutants had a defect in vivo, C57BL/6mice
were infected intraperitoneally (i.p.) with ME49, ME49myr1, or
the complemented strain ME49myr1::MYR1, and survival and
weight loss were assessed. The results (Fig. 9B) showed that all
mice infected with wild-typeME49 parasites succumbed by 9 days
postinfection (dpi), whereas all of the mice infected with
ME49myr1 mutant parasites survived. Similar results were ob-
tained with the RH lines, except that the effect of lacking MYR1
was less dramatic with a reproducible delay only in the mean time
to death: infection with the wild type and the complemented RH
lines resulted in death by 9 to 10 dpi, versus days 10 to 13 for the
RHmyr1 line (Fig. 9D). All infected mice (including the
RHmyr1-infected mice) underwent rapid weight loss (an ex-
pected symptom in mice infected with Toxoplasma) after about
day 5 (data not shown). Thus,MYR1 is necessary for full virulence
and is especially important in mouse infections with type II
strains.
DISCUSSION
Using reporter cells from transgenic mice with a c-Myc–GFP fu-
sion, we were able to isolate Toxoplasma mutants deficient in the
induction of host c-Myc. Three such mutants were characterized,
and all were found to be deficient in a single secreted protein,
dubbedMYR1.Detailed phenotyping ofmyr1mutants showed a
profound defect in the induction of not only host c-Myc but also
several other phenotypes involving interaction with the host, in-
cluding the GRA16-mediated translocation of PP2A, the GRA24-
mediated phosphorylation of p38 MAPK, and the induction of
IRF1 in the presence of IFN-, mediated by an as-yet-unidentified
effector. Interestingly, however, the myr1mutants were not de-
fective in host mitochondrial association or NF-B activation,
processes mediated by the dense granule proteins MAF1 and
GRA15, respectively. These findings argue that MYR1’s role is for
only a subset of the effectors that originate in dense granules.
MAF1 is known to operate at the PVM, andGRA15’s final location
is not known (it has never been observed outside the PV/PVM),
whereas GRA16 and GRA24 clearly traffic to the host nucleus (7,
8). It appears, therefore, that MYR1 functions only in the traffick-
ing of dense granule proteins that physically translocate, in their
entirety and as soluble entities, across the PVM.
Our data do not address when or where MYR1 is cleaved into
its two domains, and the fact that both give an indistinguishable
signal by IFA leaves open the possibility that the cleavage occurs
after release from the parasites. The fact that ASP5, the enzyme
apparently responsible for the cleavage (33), is found within the
Golgi apparatus (33, 41, 42), however, strongly suggests that cleav-
age occurs prior to release and that the two domains either remain
associated or independently target the same ultimate location in
the PV/PVM. Both the N- and C-terminal domains are abundant
within the PV. The presence of two predicted TM domains in the
C-terminal domain strongly suggests that MYR1 is integral to a
membrane, likely some combination of the membranous nano-
tube system of the intravacuolar network and the PVM, both of
which appear normal by electron microscopy in the RHmyr1
mutants (S. Rastogi and M. Panas, unpublished data). Such an
association is consistent with the role of MYR1 in translocating
proteins into the host cytosol.
The splicing of the MYR1 transcript appears to differ some-
what between strains based on RNA-Seq data from many labs
available on ToxoDB: in lab strains that have been passaged in
vitro for many years, such as the common RH, GT1, and ME49
strains, the intron is removed in about 50 to 70% of the 254,470
mRNA species. In “wild” isolates that have not been passaged
routinely in the lab, such as the ~20 field isolates analyzed by
Minot et al. (43) and the type II Czech isolate used for studies of
sexual differentiation in cats (44), this first intron is rarely if ever
spliced out. As noted above, splicing out this intron results in a
protein that lacks the first 78 amino acids compared to the version
encoded by the mRNA with this intron intact, and the resulting
N-terminally truncated version of MYR1 would lack a predicted
signal peptide and thus presumably not be secreted. This suggests
that there may be some cost to secreting a large amount of MYR1
and that repeated passage in vitro selects for decreased expression
of secreted MYR1, perhaps because MYR1-mediated transport of
effectors into the host cell is crucial only in vivo, where manipula-
tion of the host’s immune response is required.
The precise role played by MYR1 in mediating the effects of
GRA16 and GRA24, including transit of GRA24 to the host nu-
cleus, is not clear. Interestingly, BLAST analysis of just the
C-terminal domain of MYR1 showed that outside Toxoplasma,
Hammondia, andNeospora, the top twomatches were a hypothet-
ical protein of Pseudomonas brasilianum (PMG1108784; E value,
0.005) and TatC, a “Sec-independent periplasmic protein translo-
case” of Halorhabdus utahensis (E value, 0.64). TatC is part of a
complex involving two other proteins, TatA and TatB, that trans-
locates folded proteins containing a twin-arginine motif in their
signal peptide across a membrane in a Sec-independent manner
(45). This system is evolutionarily conserved, being present in
archea, bacteria, chloroplasts, and plantmitochondria. Given that
MYR1 appears to play a role in translocating proteins across a
membrane (the PVM), and the putative homology was in the re-
gion that includes the two predicted transmembrane domains of
MYR1, it is tempting to speculate that MYR1 is indeed a homo-
FIG 6 MYR1 is not necessary for the ability of Toxoplasma tachyzoites to recruit host mitochondria or induce NF-B. (A) Confirmation of c-Myc phenotype.
HFFs grown in low-serummediumwere infectedwith the indicated parasites expressingmCherry for 14 h before being fixedwith formaldehyde and stainedwith
DAPI and antibodies to c-Myc. UI, uninfected. Bar, 5m. (B) Effect ofMYR1 on host mitochondrial association. The images are as described for panel A except
that HFFs were infected with the indicated Toxoplasma strains for 13 h. Host cell mitochondria were detected using an anti-TOM20 antibody (green), and
parasites were detected using the constitutively expressedmCherrymarker in each strain (red). (C) Effect ofMYR1 on nuclear NF-B accumulation. The images
are as described for panel A except that ME49, ME49myr1, and ME49myr1::MYR1 parasites were used to infect HFFs for 30 h, at which time cells were fixed
and stained with anti-SAG1 antibody (red) and anti-NFB antibody (green). (D, E, and F) c-Myc induction, HMA, and nuclear NF-B accumulation were
quantified. Data are means and standard errors of the means (SEM) from three independent assessments. **, P 0.01.
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FIG 7 MYR1 is necessary for the function of several effectors, including GRA16 and GRA24. (A) Effect of MYR1 on GRA24-mediated p38 MAPK activation.
An immunofluorescence assaywas performedon confluentHFFs thatwere uninfected or infectedwith the indicated strains. At 20 hpi, cells were fixed and stained
using anti-phospho-p38MAPK antibody. Bar, 5m. (B) Effect ofMYR1 onGRA16-mediated PP2A nuclear translocation. The images are as described for panel
A except that cells were stained using antibody to the PP2A-B subunit. (C) Role for MYR1 in the block of IFN--induced IRF1 activation. The images are as
described for panel A except that HFFs were infected for 14 hwith the indicated parasites expressingmCherry, stimulated with 200 units/ml of IFN- for 6 h, and
fixed with formaldehyde. Cells were stained using anti-IRF1 antibody. White arrowheads highlight the host nuclei in infected cells. UI, uninfected. (D, E, and F)
p38 phosphorylation and nuclear accumulation, PP2A nuclear translocation, and IRF1 nuclear accumulation were quantified. Data are means and SEM from
three independent assessments. **, P 0.01.
Franco et al.
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logue of TatC, even though the E value was weak. BLAST analysis
of the Toxoplasma genome with the TatA and TatB proteins did
not reveal any apparent homologues (data not shown), but given
the very weak extent of similarity between MYR1 and TatC, or-
thologues may not be readily detected by this method. Future
studies aimed at isolation of MYR1-associated proteins will help
address this and the question of whether the N- and C-terminal
domains of MYR1 associate in infected cells.
Our data do not address whether one or both portions of
MYR1 are necessary for the c-Myc up-regulation and the other
MYR1-dependent phenotypes described here. Given the tantaliz-
ing similarity of the C-terminal domain to TatC, we attempted to
ectopically express this domain, including the ASP5-dependent
cleavage site, fused to the MYR1 signal peptide, but the resulting
protein was not stably expressed. It may be that proper folding,
secretion, and/or localization within the PV/PVM of both do-
mains is dependent on their being synthesized as a single protein
to start.
Our results showing attenuated virulence of the myr1 mu-
tants indicate a role for MYR1 in the pathogenesis of Toxoplasma
in mice, especially for type II strains likeME49.While not directly
demonstrated, such a role forMYR1 seems likely to be through its
impact on several key pathways that Toxoplasma tachyzoites dis-
rupt in the infected cell: c-Myc, p53, p38 MAPK, and IRF1. All
these data are consistent with the fact thatMYR1 is dispensable for
growth in vitro.
No obvious orthologue of MYR1 is detectable in the related
parasite Plasmodium falciparum, which is also known to translo-
cate proteins across the PVM, in this case into the erythrocyte
cytosol (13–15). This suggests that either the machinery has di-
FIG 8 MYR1 plays a role in translocation of GRA24 to the host nucleus. HFFs
were infectedwithRH-WT,RHmyr1, or RHmyr1::MYR1 parasites express-
ing a Myc-tagged GRA24, and at 20 hpi, the cultures were fixed and stained
with antibodies to the Myc tag. Bar, 5 m.
FIG 9 MYR1 mutants exhibit wild-type growth in vitro but decreased virulence in mice. (A) Growth comparison of ME49 strains in vitro. HFF were
infected with the indicated strains of parasites for 22 h, and the number of parasites in each vacuole was then assessed. The percentage of vacuoles
demonstrating 2, 4, 8, or8 parasites per vacuole is displayed. Data are averages for two independent replicates. (B) Kaplan-Meier survival curve for mice
infected with ME49 parasites with or without MYR1. Five mice in each group were injected intraperitoneally with PBS or with 100 tachyzoites of
Toxoplasma ME49, ME49myr1, or ME49myr1::MYR1. The results are representative of two experiments with similar outcomes. (C) As for panel A,
growth of RH strains was assessed in HFFs at 16 h. The percentage of vacuoles demonstrating 2, 4, 8, or 8 parasites per vacuole is displayed. Data are
averages for two independent replicates. (D) As for panel B, survival was assessed in mice injected intraperitoneally with PBS or with 100 tachyzoites of
Toxoplasma RH (5 mice per group), RHmyr1 (6 mice per group), or RHmyr1::MYR1 (5 mice per group). The results are representative of two
experiments with similar outcomes. *, P  0.05; **, P  0.01.
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verged in sequence to the extent that it is no longer identifiable by
BLAST or different machinery suffices for this purpose. Indeed,
Plasmodium spp. are known to use a PTEX complex for translo-
cating proteins across the PVM (13–15), and so perhaps that ma-
chinery functions without the need for aMYR1-like protein. Tox-
oplasma encodes a clear orthologue of at least one of the key
components of the PTEX, EXP2 (GRA17 in Toxoplasma), but this
protein has recently been shown to function in translocation of
only small molecules (under 3,000 Da), not proteins, across the
PVM (16), and so evidence for a PTEX-like machine for proteins
in Toxoplasma-infected cells does not yet exist. It seems, instead,
that the different selective pressures operating in the host cells
occupied by Toxoplasma and Plasmodium (most nucleated cells
and erythrocytes, respectively) may have resulted in the evolution
of distinct translocation systems for these two important parasites.
All three mutants produced by our screen and selected for fur-
ther analysis were defective in MYR1. While this indicates that
MYR1 is a major player in the phenotype that was the basis of our
screen (up-regulation of c-Myc upon Toxoplasma infection), it
does not exclude the possibility that mutations in other key genes
will be among the other mutants obtained but not yet character-
ized. Indeed, the recent results of Coffey et al. showing that the
asp5 mutant is defective in c-Myc up-regulation (33) predicts
that, were it not for their growth defect in vitro, ASP5 mutants
should be present in ourmutant set. Given the pleiotropic pheno-
type of the myr1mutants, MYR1 seems unlikely to be the actual
effector driving c-Myc up-regulation, and so these other mutants
may lead us to that effector. It is also possible that c-Myc up-
regulation is a somewhat redundant process involving more than
one effector, in which case mutations in machinery like MYR1
might give rise to a stronger phenotype than those in a single
effector, and this would explain why all 3 mutants first examined
hadmutations in this gene. Extensive analysis of the othermutants
obtained will help answer this question.
Overall, the results presented here show that a novel exported
protein of Toxoplasma gondii is necessary for the function of sev-
eral secreted effectors and that the absence of this protein results in
a substantial attenuation of virulence in mice. The mechanism by
which this protein functions is not yet known, but the data
strongly suggest that it is involved in the transport of effectors
across the PVM, where they can then access other compartments
in the host cell.
MATERIALS AND METHODS
Parasite strains, culture, and infections. The following strains were used
in this study: Toxoplasma gondii RH CRE-toxofilin mCherry (46), Toxo-
plasma gondii ME49-luchxgprt (47), and Neospora caninum NC-1
mCherry (9). Toxoplasma and Neospora tachyzoites were propagated in
human foreskin fibroblasts (HFFs) cultured in completeDulbecco’smod-
ified Eagle medium (cDMEM) supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 2 mM L-glutamine, 100 U ml1 penicillin, and
100 g ml1 streptomycin. Prior to infection, parasites were scraped
and lysed using a 27-gauge needle, counted using a hemocytometer,
and added to HFFs. Mock infection was done by syringe-lysing unin-
fected HFFs, processing them in the same manner as the infected cells,
and then adding the same volume of the resulting material as used for
infections.
ENUmutagenesis. Toxoplasma RH CRE-toxofilin mCherry parasites
were grown in HFFs to full vacuoles and treated with cDMEM containing
1 mM N-ethyl-N-nitrosourea (ENU). After a 2-h incubation at 37°C,
mutagenized cells were washed three times for 10 s at room temperature
by rinsing the monolayer with 10 ml cold 1 phosphate-buffered saline
(PBS), scraped, syringe-lysed into 3 ml PBS, counted, and added to a new
flask with HFFs. Mutagenized parasites were expanded for 24 h in HFFs
prior to screening for c-Myc mutants. The percent killing that resulted
from ENU mutagenesis was assessed by counting plaques resulting from
mutagenized and dimethyl sulfoxide (DMSO)-treated parasites. Briefly,
100 parasites were added to a flask containing an HFF monolayer, and
plaques were counted after 10 days of incubation at 37°C.
BMM isolation, culture, and infection.Mouse bone marrowmacro-
phages (BMMs) were derived from the femurs and tibias of mice via
culture for 8 days in cDMEMplus 20% (final concentration)macrophage
colony-stimulating factor (M-CSF)-containing medium. Expanded
BMMs were infected with Toxoplasma orNeospora parasites at anMOI of
0.25 and incubated for 20 h at 37°C. Infected cells were washed and incu-
bated in 1 PBS at 4°C for 10 min. BMMs were then harvested by scrap-
ing, centrifuged, resuspended in 250 l PBS containing 0.5% FBS, and
filtered using tubes with cell strainer caps (BD Biosciences). Flow cytom-
etry analysis was performed as described below.
Flow cytometry. Infected cells were harvested by washing once with
PBS and treating with trypsin for 5 min at 37°C. After one PBS wash, cells
were resuspended in 0.5% FBS-PBS and filtered using tubes with cell
strainer caps (BD Biosciences). Fluorescence was detected by the Falstaff
BD Aria II sorter (Stanford FACS facility). Flow cytometry data were
analyzed using FlowJo.
Whole-genome sequencing. Isolatedmutant populations were singly
cloned by limiting dilution followed by expansion in HFFs. Genomic
DNA from three mutant strains and a wild-type strain was isolated using
genomic DNA Clean & Concentrator (Zymo Research).
For the DNA library preparations, 1 g of gDNA was first sheared
down to 200 to 300 bp using the Covaris S2 per the manufacturer’s rec-
ommendations. Paired-end sequencing libraries were prepared using Il-
lumina’s TruSeq PCR free sample preparation kit. The target insert size of
200 to 250 bp was size selected using SPRI Ampure XP purification. Fol-
lowing DNA library construction, library size distribution was checked
using the Agilent Bioanalyzer high-sensitivity assay. Library quantifica-
tion was done via qPCR (Stratagene MX3005P). DNA libraries were se-
quenced using the Illumina HiSeq 2000 in one lane on a flow cell with
sequencing paired-end read length at 2  50 bp. Reads were demulti-
plexed using CASAVA (version 1.8.2).
DNA sequencing data processing and SNV analysis. The DNA se-
quencing reads in Fastq format were first checked for quality using
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc).
Sequencing adapter sequences present in the reads were trimmed using
SeqPrep (https://github.com/jstjohn/SeqPrep). Sequencing reads were
then mapped using Bowtie2 (48) with default parameters against the ref-
erence genome of Toxoplasma gondii GT1 strain downloaded from Tox-
oDB (release 10.0) (49). Single nucleotide variants (SNVs) that were pres-
ent inmutant strains andnot in thewild typewere identified usingRADIA
(https://github.com/aradenbaugh/radia/) (50). RADIA used the SAM-
tools (51) (mpileup command [version 0.1.18]) to examine the base calls
at each locus of the genome in parallel for the wild type and the mutant
sample. The BAM files generated by Bowtie2 were used as input, and
output variants were in variant call format (VCF) (https://github.com/
samtools/hts-specs). For each base, the following cutoffs were used: a
minimum Phred base alignment score of 10 and a minimum Phred map-
ping quality score of 10. Additional SNVfiltering stepswere a requirement
for an overall read depth of 10 for both thewild type and themutant strain
and a minimum read depth that supported the alternative allele of 4 and
80% of the total read depth.
Western blotting. Cell lysates were prepared at 20 h postinfection
(hpi), and the total protein concentration of lysates was determined by a
Bradford protein assay (Bio-Rad). Samples containing 20 g of protein
were boiled for 5 min, separated by SDS-PAGE, and transferred to poly-
vinylidene difluoride (PVDF) membranes. c-Myc was detected by incu-
bation of membrane with rabbit anti-N-terminus c-Myc antibody (Y69;
Franco et al.
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Abcam) and followed by incubation with horseradish-peroxidase conju-
gated goat anti-rabbit IgG. The levels of horseradish peroxidase (HRP)
were detected using an enhanced chemiluminescence (ECL) kit (Pierce).
The expression of MYR1 in parasite strains was detected using mouse
anti-MYR1 primary antibodies or anti-hemagglutinin (anti-HA) anti-
bodies (in complemented parasites) and secondary goat anti-mouse IgG.
HostGAPDH levels served as a loading control:membraneswere stripped
with stripping buffer (Thermo Scientific) and stained with mouse anti-
GAPDH primary antibody and secondary HRP-conjugated goat anti-
mouse IgG antibody. The levels of HRP were measured as stated above.
SAG1 levels were used to control for the levels of parasites within the
infected cells. Again, membranes were stripped with stripping buffer and
stained with rabbit anti-SAG1 followed by staining with secondary HRP-
conjugated goat anti-rabbit IgG antibody and detecting the levels of HRP
as described above.
Generation of RHmyr1 and ME49myr1 parasites. To generate
RHmyr1 parasites, the parental RHhxgprt strain, deficient in the
hypoxanthine-xanthine-guanine phosphoribosyl transferase (HXGPRT)
gene, was used (52). Previously described pTKO2 vector (53), which car-
ries theHXGPRT gene flanked by loxP sites, was modified by flanking the
HXGPRT gene with sequences that correspond to 5= and 3= genomic re-
gions adjacent to theMYR1 open reading frame (ORF) (TGGT1_254470).
First, the right flank (3= region) was cloned into the pTKO2 vector. This
region of about ~1.2 kb was amplified from RH genomic DNA by PCR
using the primers 5=-GCGCAAGCTTCGAGAGACAAATTATCCAGCA
TTGATTC-3= (forward) and 5=-GCGCGCTAGCCCTTGTCTCTGTGT
GCAGCGC-3= (reverse). The resulting DNA fragment was then inserted
into the 3= multiple cloning site (MCS) flanking the HXGPRT gene in
pTKO2 vector usingHindIII andNheI restriction sites. Next, the 5= flank-
ing region of ~1.5 kb was generated using the following primers: 5=-GCG
CGGTACCCGCCCTGCAGGTTGAAGAACGT-3= (forward) and 5=-GC
GCCTCGAGTTCCCTCTCCTGATAACAGCTAGC-3= (reverse). This
region was cloned into the 5= MCS of the pTKO2 vector using KpnI and
XhoI restriction enzymes. Twenty-five micrograms of the resulting non-
linearized pTKO2_MYR1_KO plasmid was transfected into RHhxgprt
parasites via electroporation. Transfected parasites were cultured in HFFs
grown in 24-well plates, and after 24 h, their medium was replaced with
selective medium containing 50 g/ml mycophenolic acid and 50 g/ml
xanthine to select for parasites expressingHXGPRT. After two passages in
selective medium, parasites were single-cell cloned by limiting dilu-
tion. The resulting parasite strains were tested for HXGPRT integra-
tion at the 5= and 3= ends, and the absence of MYR1 was confirmed by
PCR using primers homologous to the MYR1 open reading frame
(data not shown). Ultimately, the loss of MYR1 expression in parasites
was confirmed by Western blotting using the mouse anti-MYR1 anti-
body (Fig. 3). To generate ME49myr1, the above-described transfec-
tion was repeated using ME49-luchxgprt (the HXGPRT-deficient
type II ME49 strain that expresses firefly luciferase). The same
pTKO2_MYR1_KO vector was used to delete MYR1 in ME49-
luchxgprt and RHhxgprt parasites.
Ectopic complementation of RHmyr1 andME49myr1 parasites.
To ectopically complement RHmyr1 parasites, the HXGPRT selection
marker flanked by loxP sites was first removed from the knockout para-
sites via CRE-mediatedDNA recombination as previously described (53).
Briefly,myr1-deficient parasites were transiently transfected with a vector
carrying CRE recombinase, and hxgprt parasites were selected using
cDMEM supplemented with 350 g/ml 6-thioxanthine. Parasites were
then single-cloned by limiting dilution and the loss of HXGPRT was con-
firmed by their inability to grow in media supplemented with mycophe-
nolic acid/xanthine. The resulting RHmyr1hxgprt strain was then used
to generate the complemented RHmyr1::MYR1 parasites by transfecting
with a vector carrying the coding region of RH MYR1. This vector was
generated by modifying the pGRA1_HA_HXGPRT vector (54): the open
reading frame (ORF) ofMYR1 lacking the stop codonwas amplified from
RH genomic DNA using the following primers: 5=-GCGCATGCATATG
CGATGCCTAGTGGCTCTTC-3= (forward) and 5=-GCGCCCATGGCG
AATTATGTGACTGACGGAAATGACG-3= (reverse). The resulting
~4.4-kb fragment was digested with NsiI and NcoI and cloned into the
pGRA1_HA_HXGPRT vector. RHmyr1hxgprt parasites were trans-
fectedwith 15g of the newly synthesized pGRA1_MYR1_HA_HXGPRT
vector, and HXGPRT parasites were selected using MPA/XAN selective
medium as described above. MYR1 expression in cloned parasites was
confirmed by Western blotting using anti-MYR1 and antihemagglutinin
(anti-HA) antibodies.
To generate ME49myr1::MYR1 complemented parasites, the above-
described steps were repeated using the ME49myr1 strain, except that
the coding region of MYR1 was amplified from the ME49 genomic DNA
using the primers described above.
C-terminal HA-tagging at the endogenous MYR1 locus. To con-
struct the vector pTKO2_MYR1_HA for C-terminal endogenous
HA-tagging of MYR1, approximately 3,000 bp of the MYR1 3= coding
sequence and hemagglutinin (HA) tag were amplified from the
pGRA1_MYR1_HA_HXGPRT complementation plasmid using the
primers 5=-GCGCGCGGCCGCCTGTGGAGCGTAGCCAATGATTTT
C-3= and 5=-GCGCGATATCCTACGCGTAGTCCGGGACGT-3=. The
resulting insert was cloned into NotI and EcoRV sites of the pTKO2
mCherry vector. The plasmid was linearized at the SmaI site in the insert,
and 25 g of the linearized plasmid was transfected by electroporation
into the RHku80hpt strain. Parasites were allowed to infect HFFs in
T25 flasks for 24 h, after which the medium was changed to complete
DMEM supplemented with 50g/mlMPA and 50g/ml XAN for HXG-
PRT selection. Parasites were passaged twice before being singly cloned
into 96-well plates by limiting dilution. Screening for correct integration
into the endogenous locus was performed by PCRusingmultiple primers,
including 5=-GATTCCCCCACCTTCTCAGACCAT-3= and 5=-GCGCgat
atcCTAcgcgtagtccgggacgt-3=, as well as by Western blotting.
Generation of polyclonal anti-MYR1 antibodies. N-terminal gluta-
thione S-transferase (GST)-fused proteins were expressed using the
pGEX-6P1 plasmid (Agilent Technologies). The N-terminal exon region
of MYR1 was amplified using the primers 5=-AGAATTCCTAGACCGAC
AAGACCAG-3= and 5=-AGCGGCCGCTTCAGGGCACACGAGATCG
C-3= (corresponding to amino acids 155 to 328, inclusive). The resulting
recombinant protein was purified from Escherichia coli (Rosetta strain;
Novagen/EMD Millipore) and injected intraperitoneally into female
BALB/c (Charles River) mice with a Sigma Adjuvant System (Sigma) ac-
cording to the manufacturer’s instructions. Blood of naive mice was
drawn prior to injection, and mice with sera that exhibited the lowest
baseline reactivity against monolayers of Toxoplasma-infected cells were
selected for antibody generation. Mice were injected with the initial dose
of 100 g protein/mouse followed by boosters of 50 g protein/mouse
on days 21, 40, 65, and 89 after the initial injection. Serum from these
mice was isolated on days 33, 51, 75, and 113 after the initial injection.
All animal experiments were conducted with the approval and over-
sight of the Institutional Animal Care and Use Committee at Stanford
University.
Immunofluorescence microscopy. Infected cells grown on glass cov-
erslips were fixed using 2.5% formaldehyde in PBS for 20 min or using
methanol, as indicated in the text. Sampleswerewashed one to three times
with PBS and blocked using 3% bovine serum albumin (BSA) in PBS for
1 h at room temperature. Cells were permeabilized with 0.2% Triton
X-100–3%BSA–PBS for 10min at room temperature.MYR1 protein was
detected with mouse anti-MYR1 or rat anti-HA primary antibodies and
secondary antibodies conjugated to 488-nm fluorochrome. c-Myc was
labeled using rabbit anti-c-Myc antibodies and 488-nm-fluorochrome-
conjugated goat anti-rabbit IgG. GRA7 protein was detected by mouse
anti-GRA7 and 594-nm-fluorochrome-conjugated goat anti-rabbit IgG.
NF-B was detected with SC-109 (Santa Cruz Biotechnology). To assess
hostmitochondrial association, infected cells were fixed 12 to 14 hpi using
2.5% formaldehyde diluted in prewarmed medium and then permeabil-
ized and blocked as described above. Mitochondria were detected with a
MYR1, a Novel Protein in Toxoplasma Virulence
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rabbit anti-TOM20 antibody (Santa Cruz Biotechnology) used at 1:100.
Phospho-p38 MAP kinase and PP2A-B subunit were labeled using rabbit
anti-phospho-p38 (Thr180/Tyr182) antibody (no. 9211; Cell Signaling
Technologies) and rabbit PP2A B subunit antibody (no. 4953; Cell Sig-
naling Technologies), respectively, followed by 488-nm-fluorochrome-
conjugated goat anti-rabbit IgG. Vectashield with 4=,6-diamidino-2-
phenylindole (DAPI) stain (Vector Laboratories) was used to mount the
coverslips on slides. Fluorescence was detected using either wide-field
fluorescence microscopy or by confocal microscopy using an LSM510 or
LSM710 inverted confocal microscope (Zeiss). Images were analyzed
using ImageJ or FIJI. All images shown for any given condition or
staining in any given comparison or data set were obtained using iden-
tical parameters.
Cell cycle assessment. RAW264.7 murine macrophage-like cells were
infected with parasites at an MOI of 3. At 19 h, cells were harvested and
split into two populations, one to assess infection rate and one to assess
cell cycle. Infection rates were approximately 97%. Cells intended for cell
cycle analysis were fixed and permeabilized withmethanol for 20min and
then stainedwith propidium iodide for 30minbefore being assessed on an
LSRII flow cytometer.
IRF1 staining. HFFs were infected at an MOI of 0.1 for 14 h before
200 units/ml of human IFN- was added. Six hours after the addition of
IFN-, cells were fixed with formaldehyde and stained with the mouse
monoclonal antibody clone 20/IRF1 (catalogue no. 612046; BD Biosci-
ences, San Jose, CA, USA).
GRA24 localization. Tachyzoite-infected HFFs were scraped and
lysed using a 27-gauge needle and spun down, and the parasites were then
electroporated with 50g of the pHTU-GRA24-3XMyc plasmid express-
ing C-terminally Myc-tagged GRA24 off the tubulin promoter (33). The
transfected andmock-transfected parasites were allowed to infect conflu-
entHFFs for 20 h before themonolayerswere fixedwith 3% formaldehyde
and stained using Myc-tag antibody (M4439; Sigma).
Mouse infections. Tachyzoites were grown inHFFs and isolated from
infected cells by scraping of the cell monolayer and syringe lysis using a
27-gauge blunt needle. After one wash in PBS, parasites were counted and
diluted in PBS. Female C57BL/6 mice were used for studies with ME49
parasites, and female CBA/J mice were used for studies with RH parasites.
Each mouse was inoculated via intraperitoneal (i.p) infection with 100
tachyzoites in a 200-l volume. Plaque assayswere performed on a sample
of the inoculum to quantify the number of viable tachyzoites in each
sample, and only experiments where comparable numbers were obtained
were included in our analyses. All animal experiments were conducted
with the approval and oversight of the Institutional Animal Care and Use
Committee at Stanford University.
Statistics. Statistical analysis was performed with Prism version 6.04
software. For c-Myc, NF-B, PP2A, p38, and IRF1, comparisons drawn
between myr1 and the wild-type or complemented strains were per-
formed using Student’s t test. For HMA association, comparison was
performed with a chi-square test. For survival curves, comparisons were
performed with a log rank Mantel-Cox test.
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